Expert Review of Pharmacoeconomics & Outcomes Research最新文献

Multicenter, cross-sectional study of the economic burden of multiple sclerosis and cost-driving factors. 多发性硬化症的经济负担和成本驱动因素的多中心横断面研究。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-07-24 DOI: 10.1080/14737167.2025.2539840

Moustafa Berrichi, Zahira Barka-Bedrane, Ahlam Osmani, Karima Belahcen, Bouchra Hafsi, Ines Messaoudi, Mohammed Adil Selka, Houari Toumi

{"title":"Multicenter, cross-sectional study of the economic burden of multiple sclerosis and cost-driving factors.","authors":"Moustafa Berrichi, Zahira Barka-Bedrane, Ahlam Osmani, Karima Belahcen, Bouchra Hafsi, Ines Messaoudi, Mohammed Adil Selka, Houari Toumi","doi":"10.1080/14737167.2025.2539840","DOIUrl":"https://doi.org/10.1080/14737167.2025.2539840","url":null,"abstract":"Background: Multiple sclerosis (MS) is a chronic neurodegenerative disease impacting young adults, reducing quality of life and imposing economic burdens.Objectives: This study estimated MS costs in Algeria from a societal perspective, analyzed cost variations by disease severity, and provided insights for enhancing MS management and healthcare planning.Methods: A cross-sectional, bottom-up cost-of-illness study used a validated questionnaire to collect demographic, clinical, and socioeconomic data from MS patients. Data included disease-modifying therapy (DMT) use, MS course, and EDSS scores. Direct costs (medical and non-medical) and indirect costs (productivity losses from absenteeism and early retirement) were calculated. Cost drivers were analyzed using generalized linear models.Results: Among 354 patients, the total annual societal cost per MS patient was $9,636.5 (95% CI: 9101.2 -10,178), with a mean EDSS score of 3.1 (SD 2.1). Direct costs accounted for 93.31%, with DMTs comprising 94.42% of direct medical costs. Costs rose with disease severity, from $8,697.9 (95% CI: 8060.9-9326.8) for mild MS to $12,450.8 (95% CI: 10137.2 -14,773.6) for severe MS (p < 0.001).Conclusions: This study highlights MS's economic burden in Algeria, with DMTs as the primary cost driver. Optimized resource allocation and cost-effective DMT strategies are essential to improve MS care.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The economic benefits of fracture prevention. 预防骨折的经济效益。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-07-24 DOI: 10.1080/14737167.2025.2539838

Lakshmi Nagendra, Manju Chandran, Mickael Hiligsmann

{"title":"The economic benefits of fracture prevention.","authors":"Lakshmi Nagendra, Manju Chandran, Mickael Hiligsmann","doi":"10.1080/14737167.2025.2539838","DOIUrl":"https://doi.org/10.1080/14737167.2025.2539838","url":null,"abstract":"Introduction: Osteoporosis-related fractures represent a significant and growing public health concern, especially in aging populations. Despite the availability of effective treatments, significant care gaps persist in both primary and secondary prevention.Areas covered: This narrative review synthesizes key findings from economic evaluations examining the cost-effectiveness of pharmacological and non-pharmacological therapies, fracture liaison services (FLS), and FRAX®-based intervention thresholds. Relevant literature was reviewed, including systematic reviews, country specific studies, and emerging data on novel technologies. The evidence consistently demonstrates that fracture prevention strategies are cost-effective across diverse healthcare settings. Pharmacological monotherapy and sequential regimens have shown favorable economic profiles, while FLS programs, although resource-intensive, significantly reduce re-fracture rates and associated costs. Intervention thresholds should be derived clinically, with health economic modeling used to evaluate their cost-effectiveness so as to guide rational, risk-based treatment strategies.Expert opinion: Health economic evaluations are increasingly enabling the development of osteoporosis treatment strategies, highlighting the strong cost-effectiveness potential of these interventions. However, challenges remain including heterogeneity in analytical approaches, underrepresentation of low- and middle-income countries, and limited incorporation of real-world (adherence) data. Maintaining methodological consistency, expanding region-specific data, and evaluating emerging technologies with robust economic frameworks are essential steps toward achieving globally equitable and cost-effective osteoporosis care.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

TearCare system versus cyclosporine ophthalmic emulsion for the treatment of moderate-to-severe meibomian gland disease associated dry eye disease in the United States: a cost-utility analysis. 在美国，TearCare系统与环孢素眼用乳剂治疗中重度睑板腺病相关干眼病：成本效用分析

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-07-24 DOI: 10.1080/14737167.2025.2537850

Nathan Lighthizer, Bonnie-Kim Schwertz, Thomas Chester, Roberta Longo, Phoenix Riley, Lorie Mody, Chad Patel

{"title":"TearCare system versus cyclosporine ophthalmic emulsion for the treatment of moderate-to-severe meibomian gland disease associated dry eye disease in the United States: a cost-utility analysis.","authors":"Nathan Lighthizer, Bonnie-Kim Schwertz, Thomas Chester, Roberta Longo, Phoenix Riley, Lorie Mody, Chad Patel","doi":"10.1080/14737167.2025.2537850","DOIUrl":"https://doi.org/10.1080/14737167.2025.2537850","url":null,"abstract":"Background: Meibomian gland disease (MGD) is a leading cause of dry eye disease (DED), yet current treatments like over-the-counter and prescription drops provide only symptomatic relief. TearCare is an FDA-cleared, in-office procedure that directly targets MGD, but its cost-effectiveness has not been previously evaluated.Research design and methods: We conducted a cost-utility analysis (CUA) comparing TearCare with topical cyclosporine 0.05% (CsA) for moderate-to-severe MGD-related DED. A U.S. payer perspective and 1-year time horizon were used. A Markov model with 3-month cycles evaluated transitions across four Ocular Surface Disease Index (OSDI)-defined health states. Transition probabilities and persistence rates were derived from the SAHARA trial and literature.Results: TearCare provided better outcomes (e.g. more patients improving to mild/no symptoms) and was less costly ($4,916 vs $5,819), with a quality-adjusted life year (QALY) gain of 0.014. This corresponds to approximately 5.1 additional days in perfect health over 1 year. The incremental cost-effectiveness ratio (ICER) showed TearCare to be dominant (more effective and less costly).Conclusions: TearCare is a cost-effective treatment for MGD-related DED, offering both clinical benefits and cost savings over CsA.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A review of methodological aspects of economic evaluations used in NICE assessments for treatments in metastatic breast cancer. 对转移性乳腺癌治疗的NICE评估中使用的经济评估的方法学方面的回顾。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-07-20 DOI: 10.1080/14737167.2025.2537191

Jeroen Hendrikus Jacobus Paulissen, Sharon Wolters, Arjan Jacobus Postma, Niels Jacobus Postma, Maarten Jacobus Postma, Marinus Hulst

{"title":"A review of methodological aspects of economic evaluations used in NICE assessments for treatments in metastatic breast cancer.","authors":"Jeroen Hendrikus Jacobus Paulissen, Sharon Wolters, Arjan Jacobus Postma, Niels Jacobus Postma, Maarten Jacobus Postma, Marinus Hulst","doi":"10.1080/14737167.2025.2537191","DOIUrl":"https://doi.org/10.1080/14737167.2025.2537191","url":null,"abstract":"Introduction: Methodological choices need to be made during model development. These choices can influence the outcome of a National Institute for Health and Care Excellence (NICE) assessment.Areas covered: This review aims to identify, assess, and describe possible trends within the methodological aspects of economic evaluations used in NICE assessments of treatments for metastatic breast cancer (mBC). The NICE website was searched to identify technology appraisals submitted between 1 January 2009, and 31 December 2023. In this review methodological aspects are analyzed and discussed in three clusters - input data, model settings, and model outcomes - across the following characteristics: clinical trial information, quality-of-life measures, treatments used, model structure, health states, time horizon, threshold applied, and the NICE recommendations. This review provides a reference for stakeholders who want to understand previous NICE assessments of treatments for mBC, and the settings used in those, which can optimize decisions during model development.Expert opinion: Uniformity in the methodological choices made during model development and the economic evaluations can increase transparency, increase comparability, and reduce complexity of the NICE assessment.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world evidence of first-line osimertinib effectiveness in Bulgarian patients: a retrospective analysis. 保加利亚患者一线奥西替尼有效性的真实世界证据：回顾性分析。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-07-20 DOI: 10.1080/14737167.2025.2535636

Manoela Manova, Boryana Ivanova, Jeliazko Arabadjiev, Radoslav Mangaldzhiev, Assen Dudov, Daniel Penchev, Zornitsa Katrandzhieva, Lyubomir Bakalivanov, Boryana Zidarova, Dimitrina Apostolova, Mariya Vasileva, Silvia Terezova, Alexandra Savova

{"title":"Real-world evidence of first-line osimertinib effectiveness in Bulgarian patients: a retrospective analysis.","authors":"Manoela Manova, Boryana Ivanova, Jeliazko Arabadjiev, Radoslav Mangaldzhiev, Assen Dudov, Daniel Penchev, Zornitsa Katrandzhieva, Lyubomir Bakalivanov, Boryana Zidarova, Dimitrina Apostolova, Mariya Vasileva, Silvia Terezova, Alexandra Savova","doi":"10.1080/14737167.2025.2535636","DOIUrl":"10.1080/14737167.2025.2535636","url":null,"abstract":"Background: Third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) osimertinib is approved as a first-line treatment against non-small-cell lung cancer (NSCLC) harboring sensitizing EGFR mutations. Herein, we perform a retrospective analysis of real-world data on first-line osimertinib treatment among Bulgarian patients with NSCLC, comparing treatment outcomes to FLAURA results.Research design and methods: Patient data were obtained from electronic health records over a 4-year period. Baseline characteristics and endpoints (progression-free survival [PFS], objective response rate [ORR], and clinical benefit rate [CBR]) were compared. Iterative proportional fitting was performed to balance patient characteristics prior to survival analysis.Results: A total of 365 patients on first-line osimertinib were included. Partial responses were more frequent in the RWE cohort (24% vs 13%), while the opposite was noted for stable disease (63% vs 80%). Complete response frequency was comparable (2% vs 1%). The ORR was higher in the real world compared to in FLAURA (26% vs 14%), whereas CBR was slightly higher in the trial (89% vs 94%). The real-world PFS was higher than reported in FLAURA (19.1 vs 18.9 months), with more favorable outcomes in the RWE cohort beyond 18 months.Conclusion: RWE closely aligns with FLAURA results, suggesting even greater benefit of first-line osimertinib in the real-world setting.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-7"},"PeriodicalIF":1.8,"publicationDate":"2025-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144642186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost effectiveness of non-pharmacological interventions for fatigue in patients with long-term conditions: a systematic literature review. 长期疲劳患者非药物干预的成本效益：系统文献综述。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-07-20 DOI: 10.1080/14737167.2025.2537194

Sarah Davis, Mon Mon-Yee, Anthea Sutton, Joanna Leaviss, Jessica E Forsyth, Christopher Burton

{"title":"Cost effectiveness of non-pharmacological interventions for fatigue in patients with long-term conditions: a systematic literature review.","authors":"Sarah Davis, Mon Mon-Yee, Anthea Sutton, Joanna Leaviss, Jessica E Forsyth, Christopher Burton","doi":"10.1080/14737167.2025.2537194","DOIUrl":"https://doi.org/10.1080/14737167.2025.2537194","url":null,"abstract":"Introduction: We aimed to assess the cost-effectiveness of non-pharmacological interventions for fatigue in patients with chronic conditions in the UK.Methods: This systematic review of cost-effectiveness studies aligns with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 2020 statement. Data sources: Electronic databases and citation searches. Inclusion criteria: Studies including adults with one or more long-term health condition, either physical or mental. Exclusion criteria: Studies associated with cancer, long-COVID, post-viral fatigue, medically unexplained conditions, developmental disorders and injuries. Assessment: A single reviewer completed a two-stage sifting process.Results: Four studies met the inclusion criteria. They included patients with either multiple sclerosis or inflammatory rheumatic conditions, and assessed either cognitive behavioral therapy (CBT) or a personalized exercise programme (PEP). CBT was either dominated by usual care or had an incremental cost-effectiveness ratio (ICER) over £30,000. PEP dominated CBT, with the ICER for PEP versus usual care ranging from £13,159 to £35,424.Conclusions: The economic literature on this topic is much more limited than the clinical effectiveness literature, both in terms of interventions and populations covered. Future research should focus on a de novo economic evaluation to identify interventions with a high potential to be cost-effective across multiple conditions.Registration: PROSPERO (CRD42023440141).","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144674261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Robot-assisted medication management in home care and long-term care settings: a mixed-Method systematic review. 家庭护理和长期护理环境中的机器人辅助药物管理：混合方法系统综述。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-07-20 DOI: 10.1080/14737167.2025.2537190

Maryam Maleki, Abbas Mardani, Edris Kakemam, Ariadna Huertas-Zurriaga, Mojtaba Vaismoradi

{"title":"Robot-assisted medication management in home care and long-term care settings: a mixed-Method systematic review.","authors":"Maryam Maleki, Abbas Mardani, Edris Kakemam, Ariadna Huertas-Zurriaga, Mojtaba Vaismoradi","doi":"10.1080/14737167.2025.2537190","DOIUrl":"https://doi.org/10.1080/14737167.2025.2537190","url":null,"abstract":"Introduction: Medication errors and non-adherence among older adults in home and long-term care settings are significant concerns driven by factors such as polypharmacy, cognitive decline, and caregiver burden. Emerging technologies, such as medication management robots (MMRs), present promising solutions but necessitate rigorous, systematic evaluation. This review synthesizes the experiences of patients and caregivers, assesses the effectiveness of MMR in enhancing medication safety and minimizing errors, and offers insights into its broader implications for elderly home care.Methods: A mixed-methods systematic review was conducted using PRISMA guidelines. Searches were performed across six databases - PubMed, Scopus, Web of Science, Embase, CINAHL, and ProQuest - without publication date limits. Studies were appraised using the Mixed Methods Appraisal Tool (MMAT), and findings were synthesized through a convergent approach.Results: Six studies (3 qualitative, 2 quantitative, 1 mixed-methods) from Sweden, Finland, and the U.S.A. were included. MMRs improved adherence, reduced medication errors, enhanced coordination among healthcare providers, and supported patient autonomy. Key challenges involved technical issues, such as incompatibility with liquid medications, concerns about privacy, and reluctance from users due to diminished human contact.Conclusion: MMRs show promise in elderly care, but successful adoption depends on structured training, ethical safeguards, and user-centered design. Further research is required to validate their long-term impact and optimize implementation strategies.Registration: The protocol for this review was registered with PROSPERO (registration number: CRD42024611310): https://www.crd.york.ac.uk/PROSPERO/view/CRD42024611310.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144674262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenges with integrating early-stage cancer trial endpoints into economic models: review of health technology recommendations for adjuvant or neoadjuvant therapies in Canada. 将早期癌症试验终点纳入经济模型的挑战：加拿大辅助或新辅助治疗的卫生技术建议综述

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-07-14 DOI: 10.1080/14737167.2025.2525224

Jaclyn M Beca, Stephanie Gosselin, Don Husereau, Eon Ting

{"title":"Challenges with integrating early-stage cancer trial endpoints into economic models: review of health technology recommendations for adjuvant or neoadjuvant therapies in Canada.","authors":"Jaclyn M Beca, Stephanie Gosselin, Don Husereau, Eon Ting","doi":"10.1080/14737167.2025.2525224","DOIUrl":"10.1080/14737167.2025.2525224","url":null,"abstract":"Objectives: Adjuvant and neoadjuvant therapies for early-stage cancers demonstrate early clinical benefit in delaying disease recurrence. Health technology assessments require economic evaluations modeling lifetime disease trajectories. We examined modeling approaches used in Canadian health technology reviews to understand relevant challenges and identify opportunities for methodological improvements.Methods: From CDA-AMC reimbursement recommendations for adjuvant/neo-adjuvant treatment of solid tumors, we collected outcomes and details of submitted clinical and economic evidence. We classified issues raised during economic review related to data maturity, surrogacy, treatment pathways, and assumptions surrounding extrapolation, duration of benefit and cure.Results: Reviews from Jul/2015-Mar/2023 were identified. Reimbursement was recommended in 14/18 (78%) reviews. All assessments described OS as immature. Most (9/10, 90%) reviews with interim comparative OS data recommended reimbursement, while several (3/8, 38%) without OS data were not recommended. CDA-AMC revisions changed implications for cost-effectiveness ($50,000/QALY threshold) in 10/18 (56%) reviews. Duration of benefit assumptions was inconsistent among both submitters and reviewers. Cure-time was consistently revised to ≥5 years from initiation.Conclusions: Despite surrogate endpoints and immature survival data, positive reimbursement recommendations were common. CDA-AMC re-analyses frequently had modest impacts on cost-effectiveness. Further guidance is needed to capture benefits and assess uncertainties with more consistency for early-stage cancers.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-11"},"PeriodicalIF":1.8,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144527096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Switching hemophilia A patients to an extended half-life agent on a prophylactic basis: an economic appraisal. 在预防的基础上将血友病患者转换为延长半衰期的药物：经济评估。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-07-12 DOI: 10.1080/14737167.2025.2532805

Konstantinos Drakos, Ariston Karagiorgis, Olga Katsarou, Efrosyni Nomikou, Sofia Vakalopoulou, Marina Economou, Helen Pergantou

{"title":"Switching hemophilia A patients to an extended half-life agent on a prophylactic basis: an economic appraisal.","authors":"Konstantinos Drakos, Ariston Karagiorgis, Olga Katsarou, Efrosyni Nomikou, Sofia Vakalopoulou, Marina Economou, Helen Pergantou","doi":"10.1080/14737167.2025.2532805","DOIUrl":"10.1080/14737167.2025.2532805","url":null,"abstract":"Background: Gaining an understanding of transitioning hemophilia patients to an extended half-life (EHL) agent requires real-world data, encompassing various outcomes, which would help assessing the impact of the switch, for patients and the healthcare system. We investigate the economic implications of switching from standard half-life (SHL) recombinant factor VIII (rFVIII) from either prophylaxis or on-demand, to EHL rFVIII efmoroctocog alfa (FVIIIFc) prophylaxis.Research design and methods: The study involved 48 patients with hemophilia A from the 5 specialized hemophilia centers in Greece. Patients switched from prophylactic or on-demand treatment using a SHL factor VIII to a rFVIIIFc on prophylaxis only. Data was gathered for the 12-month period before and after switch. Using standard t-tests and regression analysis, we compared the direct treatment cost between the pre and post switch time, focusing on regimens' differential costs.Results: There is no statistically significant cost increase compared to the core rFVIII regimen used before the switch, when only patients that were previously on prophylaxis were considered. However, there is a statistically significant reduction in cost across treatment styles.Conclusions: The analysis confirms the advantages offered by prophylaxis with rFVIIIFc from an economic standpoint for the Greek healthcare system, in accordance with other studies.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-8"},"PeriodicalIF":1.8,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144599867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incorporating diagnostic testing into economic evaluations of tumour-agnostic therapies. 将诊断测试纳入肿瘤不可知论治疗的经济评估。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-07-09 DOI: 10.1080/14737167.2025.2532023

Tamás Zelei, Gábor Kovács, Shirin Ashrafganjouei, Tamás Ágh

{"title":"Incorporating diagnostic testing into economic evaluations of tumour-agnostic therapies.","authors":"Tamás Zelei, Gábor Kovács, Shirin Ashrafganjouei, Tamás Ágh","doi":"10.1080/14737167.2025.2532023","DOIUrl":"10.1080/14737167.2025.2532023","url":null,"abstract":"Introduction: Tumor-agnostic treatments represent paradigm shift in oncology, targeting specific genetic mutations irrespective of the tumor's anatomical origin. This personalized approach relies on companion diagnostic testing to identify patients likely to respond to treatment. However, incorporating molecular diagnostics poses challenges to healthcare systems, particularly regarding costs and accessibility. This must be addressed in economic evaluations to guide health technology assessment and reimbursement decisions.Areas covered: This study reviewed economic evaluations of tumor-agnostic therapies, focusing on the role of diagnostic testing. A literature search identified 13 compounds targeting nine molecular alterations, with eight relevant publications analyzed. The review revealed heterogeneity in how diagnostic testing is incorporated into cost-effectiveness models. While some studies excluded the costs and consequences of diagnostic tests entirely, others included them partially or fully. Key findings underscore the substantial impact of testing, particularly for low-prevalence biomarkers.Expert opinion: Integrating diagnostic testing into economic evaluations is essential for accurately assessing the health economic value of tumor-agnostic therapies. Economic models must account for test-treatment combinations and consider shifts in treatment pathways compared to routine practice. As the field evolves, the development of robust frameworks and clear guidance on the requirements are crucial to support sustainable and equitable healthcare decision-making.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-6"},"PeriodicalIF":1.8,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0